# Randomized Adaptive Platform Trial of Pathogen-Directed Anti-inflammatory Therapy in Severe Community-Acquired Pneumonia(Core Protocal)

> **NCT07152587** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Qingyuan Zhan** · enrollment: 1500 (estimated)

## Conditions studied

- Severe Community-acquired Pneumonia (sCAP)

## Interventions

- **DRUG:** Low dose steroids
- **DRUG:** Moderate dose steroids
- **DRUG:** Saline (0.9% NaCl)

## Key facts

- **NCT ID:** NCT07152587
- **Lead sponsor:** Qingyuan Zhan
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-08
- **Primary completion:** 2035-12-31
- **Final completion:** 2035-12-31
- **Target enrollment:** 1500 (ESTIMATED)
- **Last updated:** 2025-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07152587

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07152587, "Randomized Adaptive Platform Trial of Pathogen-Directed Anti-inflammatory Therapy in Severe Community-Acquired Pneumonia(Core Protocal)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07152587. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*